However, taking into account the serious side effects of PPAR activators, such as the higher incidence of myocardial infarction observed in clinical trials, further work is required to delineate the intricacies of modulating their activity for optimal therapeutic benefit. This evidence concerns the gene PPARA and myocardial infarction.